CD20‐depleting therapy in autoimmune diseases: from basic research to the clinic
- 1 February 2010
- journal article
- review article
- Published by Wiley in Journal of Internal Medicine
- Vol. 267 (3), 260-277
- https://doi.org/10.1111/j.1365-2796.2009.02207.x
Abstract
Perosa F, Prete M, Racanelli V, Dammacco F (University of Bari Medical School, Bari, Italy). CD20-depleting therapy in autoimmune diseases: from basic research to the clinic (Review). J Intern Med 2010; 267: 260-277. The B lymphocyte-associated antigen CD20 is becoming an important immunotherapy target for autoimmune diseases, although its biological function has not been defined. Besides rheumatoid arthritis, growing experience with B cell-depleting therapy indicates that it may be effective in Sjögren's syndrome, dermatomyositis-polymyositis, systemic lupus erythematosus and some types of vasculitides. However, controlled clinical trials are still lacking for some of these indications. Infection has not been seen as a major limitation to this therapy, but reports of progressive multifocal leukoencephalopathy in an extremely small number of patients are of concern. Here, we review the therapeutic actions of anti-CD20 antibodies, and the recent and ongoing clinical trials with CD20-depleting therapy in autoimmune diseases. © 2010 Blackwell Publishing LtdKeywords
This publication has 104 references indexed in Scilit:
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- Idiotype vaccination for lymphoma: moving towards optimisationLeukemia & Lymphoma, 2009
- Rituximab in refractory pemphigus vulgarisDermatologic Therapy, 2008
- Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysisAnnals of Hematology, 2007
- A Single Cycle of Rituximab for the Treatment of Severe PemphigusNew England Journal of Medicine, 2007
- Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomideClinical Rheumatology, 2007
- Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesisNature Clinical Practice Rheumatology, 2007
- Rituximab therapy for childhood-onset systemic lupus erythematosusThe Journal of Pediatrics, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004